Press Release
Lund, Sweden, May 11, 2023

ImmuneBiotech AB, a leading probiotic and microbiome company, is proud to announce the appointment of Dr. Kristin Wannerberger to its board of directors. Dr. Wannerberger is an internationally renowned expert in microbiome research and pharmaceuticals, and her extensive experience and expertise will be instrumental in guiding ImmuneBiotech’s strategic direction and future growth.

“We are thrilled to welcome Dr. Kristin Wannerberger to our Board of Directors”, said Shahram Lavasani, founder and CEO of ImmuneBiotech. “Her impressive background in the microbiome and pharmaceutical industries, as well as her
extensive network across both industry and academia, will have a major impact on ImmuneBiotech’s value and future product development. We look forward to incorporating her expertise in our internationalization and scaling up businesses to further strengthen our global position.”

Dr. Wannerberger’s appointment to the board of directors is part of ImmuneBiotech’s ongoing commitment to expanding its capabilities and driving innovation in the probiotics and microbiome space. It further underscores the dedication to providing the customers with the highest quality products and services.

“I am honored to be joining ImmuneBiotech’s team and to have the opportunity to contribute to the company’s ongoing success,” said Dr. Kristin Wannerberger. “The company has evolved very positively during the last years, and I have great
confidence in ImmuneBiotech’s research capabilities. I am excited to work with Shahram and the team to continue developing high-quality probiotics and microbiome solutions that have a positive impact on human health. The upcoming
products that ImmuneBiotech is developing are particularly exciting, and I look forward to helping bring them to market.”

Kristin Wannerberger currently holds a position as Director Alliance Management R&D at Ferring Pharmaceuticals, Switzerland. Ferring is a leading pharma company in the microbiome space and was the first company to get FDA-approval for a microbial treatment, Rebyota for treatment of Clostridium difficile infection. At Ferring Dr Wannerberger serves as an expert on the microbiome field and she is also directing several external research alliances in the areas of gastrointestinal and reproductive medicine. Dr Wannerberger is managing a research collaboration with the Karolinska Institute (Stockholm) where the focus is to understand the role of the microbiome in health and disease. She is also responsible for clinical research collaborations with Intralytix (US) and the Eliava Foundation (Georgia). Dr Wannerberger holds a Ph.D. in Biophysical Technology and a M.Sc. Chemical Engineering Food and Dairy Technology, both from Lund University, Sweden.